alaproclate alaproclate alaproclate (developmental code name gea-654) is a drug that was being developed as an antidepressant by the swedish pharmaceutical company astra ab (now astrazeneca) in the 1970s. it acts as a selective serotonin reuptake inhibitor (ssri), and along with zimelidine and indalpine, was one of the first of its kind. development was discontinued due to the observation of liver complications in rodent studies. in addition to its ssri properties, alaproclate has been found to act as a non-competitive nmda receptor antagonist, but does not have discriminative stimulus properties similar to phencyclidine. alaproclateclinical dataroutes ofadministrationoralatc coden06ab07 (who) legal statuslegal status in general: uncontrolled identifiers iupac name 1-(4-chlorophenyl)-2-methylpropan-2-yl 2-aminopropanoate cas number60719-82-6 n 60719-83-7 (hydrochloride)pubchem cid2081chemspider1997 yuniic4r42570zokeggd02787 ychemblchembl36591 ycomptox dashboard (epa)dtxsid5045122 chemical and physical dataformulac13h18clno2molar mass255.74 g·mol−13d model (jsmol)interactive image smiles clc1ccc(cc1)cc(oc(=o)c(n)c)(c)c inchi inchi=1s/c13h18clno2/c1-9(15)12(16)17-13(2,3)8-10-4-6-11(14)7-5-10/h4-7,9h,8,15h2,1-3h3 ykey:fzspjbyokqpkcd-uhfffaoysa-n y ny (what is this?) (verify) synthesis method for treatment of senile dementia: synthesis: patent: radiolabelled: the grignard reaction between methyl 4-chlorophenylacetate (1) with methylmagnesium iodide gives 1-(4-chlorophenyl)-2-methyl-2-propanol (2). acylation with 2-bromopropionyl bromide (3) gives 2-bromopropanoate, cid:13695101 (3). displacement of halogen with ammonia leads to alaproclate (4).